Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2014 1
2015 1
2016 2
2017 2
2022 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
Hwang ES, Hyslop T, Lynch T, Ryser MD, Weiss A, Wolf A, Norris K, Witten M, Grimm L, Schnitt S, Badve S, Factor R, Frank E, Collyar D, Basila D, Pinto D, Watson MA, West R, Davies L, Donovan JL, Shimada A, Li Y, Li Y, Bennett AV, Rosenberg S, Marks J, Winer E, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Carey LA, Thompson AM, Partridge AH; COMET Study Investigators. Hwang ES, et al. JAMA. 2025 Mar 18;333(11):972-980. doi: 10.1001/jama.2024.26698. JAMA. 2025. PMID: 39665585 Free PMC article. Clinical Trial.
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.
Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, Shimada A, Li Y, Li Y, Lynch T, Frank E, Collyar D, Basila D, Pinto D, Weiss A, Wolf A, Norris K, Witten M, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Darai S, Carey L, Thompson A, Hwang ES; COMET Study Consortium. Partridge AH, et al. JAMA Oncol. 2025 Mar 1;11(3):300-309. doi: 10.1001/jamaoncol.2024.6556. JAMA Oncol. 2025. PMID: 39665588 Clinical Trial.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV, Beitsch PD, Rock DT, Budway RJ, Dul CL, Kelemen PR, Ashikari AY, Baron PL, Weinstein PD, Mislowsky A, Lee LA, Beatty J, Murray MK, Dupree BB, Finn C, Corcoran K, Wang S, Menicucci AR, Yoder EB, Blumencranz LE, Dauer P, Audeh W, Whitworth PW; NBRST Investigators Group. Pellicane JV, et al. Among authors: mislowsky a. Surg Oncol. 2022 Dec;45:101885. doi: 10.1016/j.suronc.2022.101885. Epub 2022 Nov 22. Surg Oncol. 2022. PMID: 36436423 Free article.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Whitworth PW, et al. Among authors: mislowsky a. JCO Precis Oncol. 2022 Sep;6:e2200197. doi: 10.1200/PO.22.00197. JCO Precis Oncol. 2022. PMID: 36108259 Free PMC article.
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Baron P, Beitsch P, Boselli D, Symanowski J, Pellicane JV, Beatty J, Richards P, Mislowsky A, Nash C, Lee LA, Murray M, de Snoo FA, Stork-Sloots L, Gittleman M, Akbari S, Whitworth P. Baron P, et al. Among authors: mislowsky a. Ann Surg Oncol. 2016 May;23(5):1522-9. doi: 10.1245/s10434-015-5030-1. Epub 2015 Dec 29. Ann Surg Oncol. 2016. PMID: 26714960 Free PMC article.
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P, Beitsch P, Mislowsky A, Pellicane JV, Nash C, Murray M, Lee LA, Dul CL, Rotkis M, Baron P, Stork-Sloots L, de Snoo FA, Beatty J. Whitworth P, et al. Among authors: mislowsky a. Ann Surg Oncol. 2017 Mar;24(3):669-675. doi: 10.1245/s10434-016-5600-x. Epub 2016 Oct 21. Ann Surg Oncol. 2017. PMID: 27770345 Free PMC article. Clinical Trial.
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P, Whitworth P, Baron P, Rotkis MC, Mislowsky AM, Richards PD, Murray MK, Pellicane JV, Dul CL, Nash CH, Stork-Sloots L, de Snoo F, Untch S, Lee LA. Beitsch P, et al. Among authors: mislowsky am. Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. Epub 2017 Apr 26. Ann Surg Oncol. 2017. PMID: 28447218 Clinical Trial.
Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD. Whitworth P, et al. Among authors: mislowsky a. Ann Surg Oncol. 2014 Oct;21(10):3261-7. doi: 10.1245/s10434-014-3908-y. Epub 2014 Aug 7. Ann Surg Oncol. 2014. PMID: 25099655 Free PMC article.